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The Journal of Immunology
Enhanced Detection of Antigen-Specific CD4+ T Cells Using
Altered Peptide Flanking Residue Peptide–MHC Class II
Multimers
Christopher J. Holland,* Garry Dolton,* Martin Scurr,* Kristin Ladell,*
Andrea J. Schauenburg,* Kelly Miners,* Florian Madura,* Andrew K. Sewell,*
David A. Price,* David K. Cole,*,1 and Andrew J. Godkin*,†,1
Fluorochrome-conjugated peptide–MHC (pMHC) class I multimers are staple components of the immunologist’s toolbox, en-
abling reliable quantification and analysis of Ag-specific CD8+ T cells irrespective of functional outputs. In contrast, widespread
use of the equivalent pMHC class II (pMHC-II) reagents has been hindered by intrinsically weaker TCR affinities for pMHC-II, a
lack of cooperative binding between the TCR and CD4 coreceptor, and a low frequency of Ag-specific CD4+ T cell populations in
the peripheral blood. In this study, we show that peptide flanking regions, extending beyond the central nonamer core of MHC-II–
bound peptides, can enhance TCR–pMHC-II binding and T cell activation without loss of specificity. Consistent with these
findings, pMHC-II multimers incorporating peptide flanking residue modifications proved superior for the ex vivo detection,
characterization, and manipulation of Ag-specific CD4+ T cells, highlighting an unappreciated feature of TCR–pMHC-II inter-
actions. The Journal of Immunology, 2015, 195: 000–000.
T
he key molecular event that governs adaptive cellular
immunity is ab TCR binding to peptide–MHC (pMHC)
(1). In contrast to Abs, which bind diverse antigenic
structures with high affinities (KD values in the nanomolar to pico-
molar range), TCR binding is characterized by weak affinities (KD .
1 mM) and fast dissociation rates at physiological temperatures (2, 3).
Accordingly, soluble pMHC molecules must be multimerized to bind
stably on the surface of Ag-specific T cells via a slower composite
dissociation rate (half-life in the range of minutes to hours) compared
with the equivalent monomeric TCR–pMHC interaction (half-life of
seconds) (4, 5). Fluorochrome-tagged versions of such pMHC mul-
timers enable the visualization of Ag-specific T cells, often becoming
internalized to generate a durable intracellular label (6).
Since their development (4), pMHC class I (pMHC-I) multimers
have revolutionized studies of Ag-specific CD8+ T cells (7). How-
ever, pMHC class II (pMHC-II) multimer technology for the anal-
ysis of Ag-specific CD4+ T cells has progressed at a much lower
rate. Three key issues have affected the wider use of pMHC-II
multimers: 1) methodological problems with the production of
recombinant pMHC-II heterodimers; 2) typically low frequencies of
peripheral Ag-specific CD4+ T cells (4, 8–10); and 3) weak pMHC-
II multimer binding at the cell surface (11–15). It is notable in this
regard that TCR binding affinities for pMHC-II are approximately
five times weaker compared with their pMHC-I counterparts (2), a
distinction that could be linked to differences in Lck delivery by the
CD4 and CD8 coreceptors (16). Furthermore, the CD8 coreceptor
interaction with pMHC-I, which occurs at KD of ∼100–200 mM
(17–19), stabilizes the TCR–pMHC-I interaction (20) and
thereby enhances pMHC-I multimer binding avidity (20–23). In
contrast, the CD4 coreceptor binds pMHC-II with an estimated
KD of ∼200 mM to .2 mM (24), which is likely insufficient to
stabilize TCR–pMHC-II interactions at the cell surface (25, 26).
In humans, the most abundantly expressed MHC-II element on
blood-derived APCs is the HLA-DR ab heterodimer. The core
epitope is a nonamer peptide bound through a series of pockets in
the HLA-DR molecule at positions (P)1, P4, P6, and P9 (27).
However, the binding groove of the HLA-DR molecule is open at
either end, allowing longer peptides to bind with the nonbound
peptide flanking regions (PFRs) extending from the N terminus
(e.g., P22 and P21) and C terminus (e.g., P10 and P11) (28, 29).
Indeed, longer PFRs have been shown to increase peptide binding
affinity for MHC-II (30, 31). In a previous study, we eluted and
sequenced multiple ligands from a range of MHC-II molecules
and identified enrichment patterns in the nonbound PFRs, partic-
ularly basic residues at the C terminus, reflecting preferential Ag
processing mechanisms (32, 33). Moreover, basic residue substi-
tutions in the C-terminal PFR of known T cell epitopes from a
wide range of Ags, including hemagglutinin (HA), HIV-1 Gag,
myelin basic protein, tetanus toxoid, and hen egg lysozyme, can
lead to increased CD4+ T cell responses (33–35). Several mech-
anisms could potentially account for the increased immunoge-
nicity of MHC-II–restricted T cell epitopes with such “basic tails,”
including 1) enhanced processing by APCs, 2) increased peptide
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binding to MHC-II and 3) improved TCR binding to pMHC-II.
We recently used surface plasmon resonance (SPR) to show that
substitutions in the C-terminal PFR of an influenza HA epitope
could increase pMHC-II binding affinity for a wide range of dif-
ferent TCRs (35). In the present study, we examine whether this
effect can be harnessed to improve the detection and character-
ization of Ag-specific CD4+ T cells directly ex vivo.
Materials and Methods
Peptides
All peptides were synthesized commercially at .80% purity (EMC
Microcollections). The following peptides were used in this study: 1) in-
fluenza HA306–318 (Flu1), PKYVKQNTLKLAT (core epitope positions
P1–P9 underlined), 2) C-terminally modified variants of HA3062318 with
Arg at P11 (Flu3, PKYVKQNTLKLAR); and 3) HIV-1 Gag p24299–312,
DRFYKTLRAEQASQ.
Cell culture
Healthy donors were HLA genotyped using allele-specific PCRs (Welsh
Blood Transfusion Service). PBMCs were isolated from DR1+ donors by
density gradient centrifugation of heparinized blood, layered onto an equal
volume of LymphoPrep (Axis-Shield). All human samples were used in
accordance with United Kingdom guidelines. T cell lines and clones were
generated and maintained as described previously (36). Ag-specific T cell
clones 2C5, DC08, and DCD10 were derived either by limiting dilution or by
DR1-HA3062318 multimer staining and cell sorting. Clonality was confirmed
by sequencing TRA and TRB gene rearrangements. HLA restriction was
confirmed via peptide titrations in the presence of DR1-matched and DR1-
mismatched B lymphoblastoid cell lines (B-LCLs) (37).
Generation of expression plasmids
The HA1.7 and 2C5 TCRs were generated from the corresponding CD4+ T cell
clones as described previously (38). All sequences were confirmed by auto-
mated DNA sequencing (Lark Technologies). A disulfide-linked construct was
used to produce the soluble domains (variable and constant) for both the
TCRa- and TCRb-chains (39). The DRa1*0101 chain, tagged with a bio-
tinylation sequence, and DRb1*0101 chain were also cloned and used to
produce the pMHC-II molecules (40). All constructs were inserted into sepa-
rate pGMT7 expression plasmids under the control of the T7 promoter.
Protein expression and purification
Rosetta DE3 Escherichia coli competent cells were used to express the
TCRa, TCRb, DRa1*0101, and DRb1*0101 chains in the form of in-
clusion bodies as described previously (38). The DRa1*0101 and
DRb1*0101 chains were purified into 8 M urea buffer (8 M urea, 20 mM
Tris [pH 8.1], 0.5 mM EDTA, 30 mM DTT) by ion exchange using a
HiTrap Q column (GE Healthcare, Buckinghamshire, U.K) to remove
bacterial impurities. For a 1-l TCR refold, 30 mg TCRa-chain was incu-
bated for 15 min at 37˚C with 10 mM DTT and added to cold refold buffer
(50 mM Tris [pH 8.1], 2 mM EDTA, 2.5 M urea, 6 mM cysteamine hy-
drochloride, 4 mM cystamine). After 15 min, 30 mg TCRb-chain, also
incubated for 15 min at 37˚C with 10 mM DTT, was added. TCR refolds
were dialyzed against 20 vol 10 mM Tris and purified by ion exchange
(Poros 50 HQ, Life Technologies, Cheshire, U.K.) and gel filtration (S200
HR, GE Healthcare). For a 1-l pMHC-II refold, 2 mg DRa1*0101 chain
was mixed with 2 mg DRb1*0101 chain and 0.5 mg peptide for 15 min at
37˚C with 10 mM DTT (41). This mixture was then added dropwise to
cold refold buffer (25% glycerol, 20 mM Tris [pH 8.1], 1 mM EDTA, 2
mM glutathione reduced, 0.2 mM glutathione oxidized). Refolds were
incubated for 72 h at 4˚C. Subsequently, the refold mixture was concen-
trated using a VivaFlow 200 (polyethersulfone membrane) module (Sar-
torius) to a volume of#50 ml and then further concentrated to a volume of
#2 ml using a Vivaspin 20 (Sartorius). Concentrated refolds were washed
with PBS. The refold was then purified by affinity chromatography by
binding to a conformationally specific Ab (L243) and size exclusion
chromatography using a Superdex 200 HR column and an A¨KTA FPLC in
conjunction with Unicorn software. Protein quality was analyzed by
Coomassie-stained SDS-PAGE. Biotinylated pMHC-II was prepared as
described previously (42).
Surface plasmon resonance
Binding analysis was performed using a Biacore 3000 (GE Healthcare)
equipped with a CM5 sensor chip, as reported previously (43, 44). Be-
tween 200 and 400 response units of biotinylated pMHC-II was immo-
bilized on streptavidin, which was chemically linked to the chip surface.
pMHC-II was injected at a slow-flow rate (10 ml/min) to ensure uniform
distribution on the chip surface. The 2C5 TCR was purified and con-
centrated to ∼100 mM on the day of analysis to minimize TCR aggre-
gation. For equilibrium analysis, eight serial dilutions were carefully
prepared and injected over the relevant sensor chip at a flow rate of
45 ml/min at 25˚C. Results were analyzed using BIAevaluation 3.1,
FIGURE 1. The biophysical impact of
altered C-terminal PFRs on TCR binding.
SPR was used to determine equilibrium
binding of the 2C5 TCR to DR1 complexed
with either (A) native Flu1 (HA3062318,
PKYVKQNTLKLAT) or (B) altered Flu3
(PKYVKQNTLKLAR). (C) Previously pub-
lished thermodynamic analysis of the HA1.7-
DR1-Flu1 interaction (40). (D) HA1.7-DR1-
Flu3 thermodynamic properties showing
enthalpy (DHo) and entropy (TDSo) at 298 K
calculated by nonlinear regression of temper-
ature (K) plotted against free energy (DGo).
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Microsoft Excel, and Origin 6.1. The KD values were calculated using a
nonlinear curve fit [y = P1x/(P2 + x)].
Thermodynamic analysis
Thermodynamic analysis of HA1.7 TCR ligation to DR1-Flu3 was per-
formed using a Biacore T100 (GE Healthcare) equipped with a CM5 sensor
chip. Activation and pMHC-II loading were assessed as previously de-
scribed (40). A total of 500 response units of biotinylated pMHC-II were
immobilized to streptavidin, which was chemically linked to the chip
surface. Equilibrium binding analysis was performed with 10 serial dilu-
tions of the TCR individually injected at temperatures of 5, 10, 15, 20, 25,
and 30˚C. Experiments were performed in triplicate using a blank flow
cell, A2-ELAGIGILTV and DR1-CLIP as negative controls in separate
experiments. The binding response was determined by subtraction of the
response measured on a negative control flow cell from the response
measured on flow cells containing DR1-Flu3. Results were analyzed using
BIAevaluation 3.1, Microsoft Excel, and Origin 6.1. The KD values were
calculated using a nonlinear curve fit [y = (P1x)/(P2 + x)]. Thermodynamic
parameters were calculated using the nonlinear van’t Hoff equation [RT ln
KD = DH˚ 2 TDS˚ + DCp˚(T 2 T0) 2 TDCp˚ ln (T/T0)], where R is the
gas constant, T is the temperature in Kelvin (K) at which the KD is mea-
sured, T0 is the reference temperature (298.15 K = 25˚C), DH˚ is the en-
thalpy change upon binding at T0 (cal·mol
21), DS˚ is the standard entropy
change upon binding at T0 (cal·mol
21·K21), and DCp˚ is the specific heat
capacity (cal·mol21·K21).
pMHC-II multimer staining of CD4+ T cell clones
Clonal CD4+ T cells (1 3 105) specific for HA306–318 were resuspended
with 1 mg DR1-Flu1 or DR1-Flu3 multimer and incubated for 20 min at
4˚C (45). Cells were then washed twice with PBS, stained with Live/Dead
fixable violet (ViViD; Invitrogen) for 10 min at room temperature and
labeled with mouse anti-human CD4-allophycocyanin (BD Biosciences)
for 20 min at 4˚C. After two further washes in PBS, samples were acquired
directly on a FACSCanto II flow cytometer (BD Biosciences). Data were
analyzed using FlowJo software version 10 (Tree Star). All incubations
with fluorochrome-conjugated pMHC-II multimers were performed in the
dark.
Multimer dilution assay
Each multimer was serially diluted six times (1, 0.5, 0.25, 0.125, 0.0625,
0.0312, or 0.0156 mg with respect to the pMHC-II component) and used in
a final volume of 20 ml to stain 1 3 106 DR1+ PBMCs spiked at 1% with
the CD4+ T cell clone 2C5. After incubation for 20 min at 4˚C, cells were
washed twice in PBS, stained with Live/Dead fixable aqua (Invitrogen) for
FIGURE 2. pMHC-II multimers with modified PFRs enable the detection of low-frequency Ag-specific CD4+ T cell clones. Arg substitution at
P11 of the HA3062318 epitope (Flu3) substantially increases pMHC-II multimer staining. (A) Histograms showing negative control (blue), DR1-Flu1
(green), and DR1-Flu3 (purple) multimer staining of the 2C5 clone. (B) Graph showing staining MFIs generated with different multimers as in-
dicated across a range of concentrations. (C) Bar graph showing the number of CD4+multimer+ cells detected with the indicated multimers plotted
against the frequency (%) of clonal 2C5 cells spiked into PBMCs. (D) Representative flow cytometry plots showing staining with the indicated
multimers, at a concentration of 0.125 mg/1 3 106 PBMCs, across a range of 2C5 “spiked” frequencies (%) in PBMCs. The gating strategy is shown
in Supplemental Fig. 1.
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10 min at room temperature and labeled with mouse anti-human CD3-
FITC (Serotec), mouse anti-human CD4-allophycocyanin (BD Biosci-
ences), mouse anti-human CD14–Pacific Blue (Invitrogen), and mouse
anti-human CD19–Pacific Blue (Invitrogen) for 20 min at 4˚C. After two
further washes in PBS, samples were acquired directly on a FACSCanto II
flow cytometer (BD Biosciences). Data were analyzed using FlowJo
software version 10 (Tree Star).
Clone dilution assay
PBMCs (2 3 106) were spiked at 1, 0.5, 0.25, 0.125, 0.0625, or 0.0312%
with the CD4+ T cell clone 2C5. Cell mixtures were then stained with
0.125 mg multimer/1 3 106 PBMCs and labeled with Abs as described in
the previous section. Samples were acquired directly on a FACSCanto II
flow cytometer (BD Biosciences) and analyzed using FlowJo software
version 10 (Tree Star).
Multimer staining following PBMC culture
Flu1 peptide–stimulated, precultured PBMCs (53 105) were transferred to
a 96-well plate and washed with PBS. Cell pellets were resuspended in 25
nM phosphate kinase inhibitor dasatinib (Axon Medchem, Reston, VA)
and incubated for 30 min at 37˚C. For each multimer, 0.5 mg was added
directly to the cell pellet before incubating for 20 min on ice in the dark.
Where dual staining with both PE- and allophycocyanin-conjugated mul-
timers was used, 0.5 mg each was mixed per sample prior to addition to the
cell pellets. Cells were then washed twice with cold PBS, followed by
Live/Dead aqua (Life Technologies) staining to exclude dead cells. Surface
staining was subsequently performed in PBS, 2.5% FCS, and 5 mM EDTA
(FACS buffer), with the following cell surface markers: CD3-PerCP-Cy5.5
(BD Biosciences), CD4–Brilliant Violet 421 (BioLegend), CD14-FITC
(BioLegend), and CD19-FITC (BioLegend). Cells were incubated for 20
min at 4˚C in the dark before resuspending in FACS buffer for acquisition
on a FACSCanto II (BD Biosciences). Data were analyzed using FlowJo
version 10 (Tree Star).
Direct ex vivo multimer staining and phenotypic analysis of
DR1+ PBMCs
One healthy DR1+ volunteer (donor 1) was inoculated with the 2011–2012
trivalent influenza vaccine, containing the immunodominant HA306–318
epitope. Peripheral blood (50 ml) was obtained before vaccination and on
days 3, 7, 11, and 14 after vaccination, processed as described above, and
stored in liquid nitrogen. Additionally, 50 ml peripheral blood was ob-
tained from two healthy unvaccinated DR1+ volunteers (donors 2 and 3).
Frozen PBMCs were thawed and washed twice with multimer buffer (PBS,
1% FCS). PBMCs were treated with 25 nM protein kinase inhibitor
dasatinib for 60 min at 37˚C. PBMCs were then stained with 0.5 mg
pMHC-II multimer/1–43 106 PBMCs for 30 min at 4˚C, and washed with
FIGURE 3. pMHC-II multimers with modified PFRs enable enhanced detection of expanded Ag-specific CD4+ T cells. PBMCs from 4 DR1+ donors
were cultured with the HA3062318 (Flu1) peptide for 12 d. DR1-Gag multimers were used as a negative control. (A) Representative flow cytometry plots
showing DR1-Flu1, or DR1-Flu3 multimer staining of DR1+ PBMCs cultured for 12 d. (B) Dual staining performed on donor 4 using DR1-Flu1-PE/DR1-
Flu1-allophycocyanin, DR1-Flu3-PE/DR1-Flu3-allophycocyanin, DR1-Flu1-PE/DR1-Flu3-allophycocyanin, or DR1-Flu3-PE/DR1-Flu1-allophycocyanin
multimer mixes.
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ice cold PBS. PBMCs were then subsequently stained with ViViD Live⁄
Dead cell stain (Invitogen) for 10 min at room temperature followed
by a costaining Ab mixture that included mouse anti-human CD3
allophycocyanin-H7 (BD Biosciences), mouse anti-human CD4-PE-Cy5.5
(Life Technologies), mouse anti-human CD8-BV711 (BioLegend), mouse
anti-human CD14–Pacific Blue (Invitrogen), mouse anti-human CD19–
Pacific Blue (Invitrogen), mouse anti-human CD27-PE-Cy5 (Beckman
Coulter), mouse anti-human CD45RO-ECD (Beckman Coulter), and
mouse anti-human CD57-FITC (BD Biosciences) and incubated at 4˚C
for 20 min. Alternatively, cocktails contained mouse anti-human CD3-
PerCP (Miltenyi Biotec), mouse anti-human CD4-FITC (Miltenyi Bio-
tec), mouse anti-human CD8-PE (Miltenyi Biotec), mouse anti-human
CD14–Pacific Blue (BioLegend), and mouse anti-human CD19–Pacific
Blue (BioLegend). Samples from donors 2 and 3 were treated with
pMHC multimer stabilizing anti-fluorochrome Abs as described in
Tungatt et al. (46). Samples were washed with multimer buffer, resus-
pended in PBS, directly acquired on a FACSAria II (BD Biosciences), and
analyzed using FlowJo version 10 (Tree Star). The percentage shown indi-
cates the proportion of CD3+ T cells stained with each multimer reagent.
Direct cloning of CD4+DR1-Flu3+ T cells sorted with modified
pMHC-II multimers
Frozen PBMCs from day 7 postvaccination were stained as described in the
previous section. CD4+multimer+ cells were then sorted by flow cytometry
at 1 cell/well into 96-well round-bottom plates containing 5 3 104 irra-
diated allogeneic mixed PBMCs from three donors and 1 ml/ml PHA in
100 ml CD4+ T cell medium comprising RPMI 1640 (Life Technologies),
10% FCS (Sigma-Aldrich), 1% heat-inactivated human AB serum (Welsh
Blood Transfusion Service), 0.02 M HEPES (Sigma-Aldrich), 2 mM
L-glutamine (Life Technologies), 1 mM nonessential amino acids (Life
Technologies), 1 mM sodium pyruvate (Life Technologies), 100 IU/ml
penicillin (Life Technologies), 100 mg/ml streptomycin (Life Technolo-
gies), and 20 IU/ml human rIL-2 (Proleukin; University Hospital of Wales
Pharmacy). Clonal expansion plates were incubated for 7 d at 37˚C, 5%
CO2. Wells were then replenished with 100 ml CD4
+ T cell medium and
incubated for a further 7 d at 37˚C, 5% CO2. Clones were analyzed for Ag
specificity via IFN-g ELISA.
IFN-g ELISA
Clonal CD4+ T cells (10,000 per triplicate test well) were incubated
overnight with 53 104 DR1+ B-LCLs in the presence or absence of 10 mg/ml
peptide (Flu1 or Flu3). IFN-g release was quantified by ELISA according to
the manufacturer’s instructions (R&D Systems).
Results
Improved TCR affinity binding to C-terminal PFR-modified
peptides
Our previously reported biophysical data demonstrate that targeted
substitutions in the C-terminal PFRs of MHC-II epitopes can
substantially enhance TCR binding affinity (35). To extend these
preliminary results and confirm the generality of this observation,
we derived a new DR1-restricted CD4+ T cell clone (2C5) spe-
cific for the HA3062318 epitope (Flu1, PKYVKQNTLKLAT; core
binding P1–P9 nonamer underlined). The 2C5 TCR was subse-
quently cloned, expressed, and refolded as a soluble protein for
biophysical analyses. In SPR experiments, the 2C5 TCR bound
FIGURE 4. Direct ex vivo PFR-modified pMHC-II multimer staining of CD4+ T cells specific for HA306–318. Flow cytometry plots showing DR1-Flu1
and DR1-Flu3 multimer staining of PBMCs isolated ex vivo from three donors. (A) Donor 1 prevaccination, (B) donor 1 at day 7 postvaccination with the
2011–2012 trivalent influenza vaccine, (C) donor 2 without vaccination, and (D) donor 3 without vaccination. DR1-Gag and/or DR4-CLIP multimers were
used as a negative control. Multimer+ gate cut-offs were determined from the relevant fluorescence minus one (FMO) controls (Supplemental Fig. 2). The
percentage shown indicates the proportion of CD3+ T cells stained with each tetramer reagent.
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DR1-Flu3 (PKYVKQNTLKLAR) with an affinity ∼2-fold stron-
ger compared with the corresponding wild-type C-terminal PFR
sequence (Fig. 1A, 1B). This finding was reproduced with three
other DR1-restricted TCRs specific for HA3052320 (HA1.7, F11,
and C6) where binding affinity increased by ∼1.4- to 1.8-fold with
Arg substituted at P10 (Flu2, PKYVKQNTLKLRT) and by ∼2-
fold with Arg at P11 (Flu3, PKYVKQNTLKLAR) (35). These
differences in binding affinity were further verified using a DR1-
restricted TCR specific for an HIV-1 Gag-derived peptide epitope
(data not shown). Modifications to C-terminal PFRs can therefore
enhance TCR binding affinity across multiple clonotypes and
specificities, implying a general mechanism for TCR interactions
with MHC-II–presented PFRs.
In an earlier report, we explored the thermodynamics of the HA1.7
TCR interaction with DR1-Flu1, demonstrating that a net decrease in
electrostatic interactions (unfavorable enthalpy,DHo = 18 kcal/mol) and
an energetically favorable transition from order to disorder probably
mediated the binding energy of the interaction (favorable entropy,
TDSo = 23.8 kcal/mol) (40). To extend these findings, we performed a
thermodynamic analysis of HA1.7 TCR binding to both DR1-Flu1 and
DR1-Flu3 (Fig. 1C, 1D). These experiments revealed a change in
enthalpy (DHo) toward a more favorable state for the interaction with
DR1-Flu3 (18→ 16.4 kcal/mol). As predicted previously by structural
modeling (35), these data suggest an increase in net electrostatic in-
teractions compared with HA1.7-DR1-Flu1 and offer a thermodynamic
explanation for increased affinity TCR binding to an HLA-DR–pre-
sented peptide with a substituted PFR.
C-terminal PFR modifications enhance DR1 multimer staining
To determine whether increased TCR binding affinity could en-
hance the detection of CD4+ T cells using pMHC-II multimers, we
generated fluorochrome-tagged DR1-Flu1 and DR1-Flu3 multi-
mers. A large increase in mean fluorescence intensity (MFI) was
observed with the DR1-Flu3 multimer versus the DR1-Flu1
multimer when staining the 2C5 clone (Fig. 2A, gating strategy
shown in Supplemental Fig. 1). Similar marked shifts in MFI were
FIGURE 5. Phenotypic analysis of PBMCs
stained with PFR-modified multimers after
immunization with trivalent influenza vac-
cine. Top panels, Flow cytometry plots
showing (A) DR1-Flu1 and (B) DR1-Flu3
multimer staining of PBMCs from a repre-
sentative donor at day 7 postvaccination with
the 2011–2012 trivalent influenza vaccine.
Middle panels, Bivariate flow cytometry plots
showing CD27 versus CD45RO expression
on (A) DR1-Flu1 and (B) DR1-Flu3 multi-
mer+ (blue dots) and multimer2 (density
plots) cells. Bottom panels, Bivariate flow
cytometry plots showing CD45RO versus
CD57 expression on (A) DR1-Flu1 and (B)
DR1-Flu3 multimer+ (blue dots) and multi-
mer- (density plots) cells. Multimer+ gate cut-
offs were determined from the relevant fluo-
rescence minus one (FMO) controls.
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observed with other CD4+ T cell clones specific for HA3052320
(data not shown). These results demonstrate that relatively small
differences in monomeric TCR binding affinity (∼2-fold) can
substantially enhance multimer binding avidity at the cell surface.
The superior binding of DR1-Flu3 multimers was confirmed in
two further head-to-head comparisons with DR1-Flu1 multimers:
1) reagent titrations, and 2) cognate CD4+ T cell titrations. Initially,
1 3 106 DR1+ PBMCs were spiked at 1% with a Flu1-specific
CD4+ T cell clone. Although both multimers identified a CD4+
multimer+ population when used at a concentration of 1 mg/1 3
106 PBMCs, only the enhanced staining intensity observed with
the DR1-Flu3 multimer enabled clear visualization and accurate
enumeration (Fig. 2B). At lower reagent concentrations, the DR1-
Flu1 multimer failed to identify cognate CD4+ T cells. In contrast,
distinct staining was apparent with the DR1-Flu3 multimer at
concentrations down to 0.0312 mg/1 3 106 PBMCs. Unless stated
otherwise, all multimer stains were performed using 0.125 mg/13
106 PBMCs. This represents the optimal quantity of DR1-Flu3
multimer per stain that produced the greatest shift in MFI while
reducing potential nonspecific staining. Subsequently, the fre-
quency of spiked Flu1-specific CD4+ T cells was titrated to de-
termine any differences in detection sensitivity (Fig. 2C, 2D). The
DR1-Flu3 multimer displayed a far superior ability to detect
cognate CD4+ T cells across the entire range of spiked frequencies
compared with the DR1-Flu1 multimer. Indeed, precise quantifi-
cation of target CD4+ T cells with the DR1-Flu1 multimer was
challenging due to poor separation and almost impossible at fre-
quencies #0.25%.
In further experiments, we stained PBMCs from four healthy DR1+
volunteers 12 d after HA306–318 peptide stimulation (Fig. 3A). The
DR1-Flu3 multimer detected larger populations of CD4+multimer+
cells, with generally greater MFIs, compared with the DR1-Flu1
multimer in all cases. These numerical differences suggest that the
DR1-Flu3 multimer can detect lower avidity cognate CD4+ T cells
that remain unstained with the DR1-Flu1 multimer (15). We also
performed dual staining experiments in which the DR1-Flu1 and
DR1-Flu3 multimers were conjugated to different fluorochromes
(DR1-Flu1-PE/DR1-Flu3-allophycocyanin and vice versa) to deter-
mine the level of overlap between cell populations detected with
each reagent (Fig. 3B). This analysis demonstrated a very similar
pattern of staining compared with controls in which a single reagent
was used with two different fluorochromes (i.e., DR1-Flu1-PE/DR1-
Flu1-allophycocyanin and DR1-Flu3-PE/DR1-Flu3-allophycocyanin),
suggesting that most CD4+ T cells were detected by both re-
agents. In all cases, the PE reagents were brighter than the
allophycocyanin reagents, generating a degree of bias in the
analysis. However, a comparison between DR1-Flu1-PE from
dual stain 1 and DR1-Flu3-PE from dual stain 2, or DR1-Flu1-
allophycocyanin from dual stain 1 and DR1-Flu3-allophycocyanin
from dual stain 2, suggested that DR1-Flu3 was able to detect
additional, presumably lower avidity, cells compared with DR1-
Flu1.
Increased avidity of DR1-Flu3 multimers facilitates the ex vivo
characterization and isolation of cognate T cells
Antiviral immune responses typically generate large numbers of
Ag-specific CD8+ T cells that are easy to detect ex vivo using
pMHC-I multimers (47, 48). In contrast, the direct ex vivo vi-
sualization and characterization of Ag-specific CD4+ T cells has
proved problematic, often relying on additional manipulations
such as magnetic bead enrichment or sampling from compart-
ments with high precursor frequencies (8, 49, 50). To determine
whether DR1-Flu3 multimers could be used to stain CD4+
T cells directly ex vivo, PBMCs were obtained from one healthy
DR1+ volunteer before and after immunization with the 2011–
2012 trivalent seasonal influenza vaccine, which incorporates the
HA306–318 epitope, and in two further DR1
+ volunteers that were
not vaccinated. All three donors displayed robust T cell responses to
HA306–318 in IFN-g ELISPOT assays (data not shown). Direct ex
vivo multimer analysis was performed using unmanipulated
PBMCs obtained prevaccination (day 0) and at day 7 postvacci-
nation in one donor, and without vaccination in a further two
donors (Fig. 4). All gate “cut-offs” determined from relevant FMOs
are shown in Supplemental Fig. 2. In donor 1 at days 0 and 7, and
in donor 2, the DR1-Flu3 multimer stained a higher proportion of
CD4+ T cells than did the DR1-Flu1 multimer. In donor 3, al-
though the proportion of CD4+ T cells detected with each reagent
was similar, the DR1-Flu3 multimer was substantially brighter,
evidenced by a 3-fold higher MFI.
To investigate the true nature of these low-frequency CD4+
multimer+ T cell populations, we performed a comprehensive
phenotypic analysis of cellular differentiation and maturity.
Representative flow cytometry plots at day 7 postvaccination are
shown in Fig. 5. As previously shown, the DR1-Flu3 multimer
identified a larger population of CD4+ T cells compared with the
DR1-Flu1 multimer, enabling a more robust analysis of surface
FIGURE 6. Specificity of CD4+ T cells isolated with PFR-modified pMHC-II multimers. (A) Flow cytometry plot showing DR1-Flu3 multimer staining
of PBMCs from a representative donor at day 7 postvaccination with the 2011–2012 trivalent influenza vaccine. (B and C) Histograms showing multimer
staining of the CD4+ T cell clones (B) DC-C10 and (C) DC-D8 color coded as follows: multimer FMO (red), A2-ELA multimer (negative control, blue),
DR1-Gag multimer (negative control, orange), DR1-Flu1 multimer (green), and DR1-Flu3 multimer (purple). (D) Bar graph showing IFN-g release by the
CD4+ T cell clones C6, DC-C10, and DC-D8 under the indicated conditions determined via ELISA.
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marker expression. The CD4+multimer+ populations contained a
greater percentage of central memory (CD27+CD45RO+) cells
(.80%) and a lower percentage of naive (CD27+ CD45RO-)
cells compared with the CD4+multimer2 populations. Most
cells in both the multimer+ and multimer2 compartments were
CD572, consistent with a low incidence of CD4+ T cell se-
nescence (51).
To confirm that the DR1-Flu3 multimer identified a population of
CD4+ T cells specific for the HA306–318 epitope, we sorted and
cloned multimer+ cells directly from unmanipulated PBMCs
(Fig. 6A). Two clones (DC-C10 and DC-D8) were generated using
this procedure, each of which stained with the DR1-Flu1 and
DR1-Flu3 multimers (Fig. 6B, 6C). Moreover, both clones re-
leased IFN-g after stimulation with cognate peptide–pulsed DR1+
B-LCLs (Fig. 6D).
Discussion
Soluble fluorochrome-conjugated multimeric pMHC-I molecules
have revolutionized the field of cellular immunology by enabling
the direct ex vivo visualization, enumeration, characterization, and
isolation of Ag-specific CD8+ T cell populations (4, 7). In contrast,
technical and biological constraints have hindered the develop-
ment of pMHC-II multimers for the ex vivo study of Ag-specific
CD4+ T cells (4, 8–10). As a consequence, detailed analyses of
CD4+ T cell function in humans have relied on laborious en-
richment procedures (7, 45, 52–54) and/or studies restricted to
anatomical compartments more directly affected by the immune
response of interest (49, 55). However, such approaches are not
universally successful (11–14), most likely due to weaker TCR
binding affinities and a lack of CD4 coreceptor stabilization.
Cumulatively, these factors negatively impact the binding avidity
of pMHC-II multimers and thereby intrinsically limit the utility of
these reagents for the comprehensive identification of functional
Ag-specific CD4+ T cells.
Although the MHC-I and MHC-II peptide-binding grooves are
very similar in overall conformation, both comprising two “sides”
formed from a helices and a floor of b sheets, the nature of the
bound peptide in each MHC class is distinct. For example, the
MHC-I binding groove is “closed” at both ends, with two main
anchors at the N and C terminus of the peptide (56). This con-
formation generally forces longer peptides to bulge in the center to
accommodate extra residues (57). In contrast, the MHC-II peptide
groove is open at each end, enabling the core 9-mer peptides to
bind in a stretched conformation and extend beyond the limits of
groove, forming PFRs (27). This presentation mode is mediated
by MHC-II binding pockets that interact with peptide positions
P1, P4, P6, and P9 via a network of electrostatic interactions.
Modification of this network has been shown to directly alter
pMHC-II stability, demonstrating the importance of these inter-
actions for the stable display of epitopes at the cell surface for
T cell interrogation (58, 59). Peptide modifications at these key
binding sites, as well as in other positions along the 9-mer core,
have also been shown to directly affect the sensitivity of CD4+
T cells (60–64). Included in these studies are multiple examples of
single peptide substitutions in the core 9-mer region of the epitope
that select different T cell specificities, demonstrated by T cell
activation and/or tetramer binding (60, 61). Intriguingly, the open
nature of the MHC-II binding groove also enables the possibility of
multiple peptide binding registers. Similarly to single peptide sub-
stitutions, the presentation of the same epitope in multiple registered
has been shown to alter T cell specificity, with particular relevance to
type 1 diabetes (60, 61).
Additionally to alterations in the core regions of the peptide, we have
demonstrated that antigenic epitopes incorporating PFR modifications
can augment T cell activation via enhanced TCR binding to pMHC-II
(35). In the present study, we generated multimeric DR1 heterodimers
refolded with wild-type or PFR-modified peptides to assess the po-
tential benefits of this approach in an ex vivo setting. Our data show
unequivocally that “basic tail” substitutions in the C-terminal PFR can
dramatically enhance the avidity of pMHC-II multimers for cognate
CD4+ T cells. Moreover, such PFR-modified pMHC-II multimers
proved superior in head-to-head comparisons with their wild-type
counterparts, enabling the reliable detection of Ag-specific CD4+
T cells by flow cytometry. These findings offer a generic solution to the
problem of “missing clonotypes” that lie below the avidity threshold
required for detection with conventional pMHC-II multimers (15). We
have previously shown that modifications to PFRs can increase TCR
binding in other MHC-II alleles, such as HLA-DR*0401 (35). Because
the presentation of peptides by MHC-II molecules seems to be rela-
tively conserved, we are hopeful that PFRmodifications could have far-
reaching utility to improve the avidity of tetramer reagents in a wide
range of MHC-II systems.
To extend these findings, we conducted a detailed ex vivo
phenotypic analysis of Ag-specific CD4+ T cells expanded by
influenza vaccination. The DR1-Flu3 PFR-modified multimer iden-
tified a larger population of cognate CD4+ T cells compared with
the wild-type DR1-Flu1 multimer, enabling a more robust phe-
notypic evaluation of the vaccine-induced immune response. A
marked enrichment of central memory (CD27+CD45RO+) cells
was apparent in the multimer+ population relative to the CD4+
T cell compartment as a whole. Moreover, these cells were spe-
cifically expanded after vaccination. These data demonstrate the
practical application of PFR-modified multimers for the ex vivo
characterization of Ag-specific CD4+ T cells.
Collectively, our results indicate that tailored PFR modifications
can overcome intrinsic constraints that limit the utility of wild-type
pMHC-II multimers in ex vivo analyses of Ag-specific CD4+ T cell
populations. Although further work is required to confirm these
findings in other systems, we anticipate that our approach will be
broadly applicable across Ag specificities and restriction elements,
providing a much needed addition to the immunologist’s toolbox.
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